NAFLD and thyroid function: pathophysiological and therapeutic considerations

被引：53

作者：

Hatziagelaki, Erifili ^{[1
]}

Paschou, Stavroula A. ^{[2
,3
]}

Schoen, Martin ^{[4
,5
]}

Psaltopoulou, Theodora ^{[2
,3
]}

Roden, Michael ^{[4
,5
,6
,7
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Diabet Ctr, Dept Internal Med 2, Athens, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Hosp, Endocrine Unit,Dept Clin Therapeut, Athens, Greece

[3] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Diabet Ctr, Sch Med,Dept Clin Therapeut, Athens, Greece

[4] Heinrich Heine Univ Dusseldorf, Inst Clin Diabetol, German Diabet Ctr, Leibniz Ctr Diabet Res, Dusseldorf, Germany

[5] German Ctr Diabet Res DZD, Partner Dusseldorf, Munich, Germany

[6] Heinrich Heine Univ Dusseldorf, Dept Endocrinol & Diabetol, Med Fac, Dusseldorf, Germany

[7] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Dusseldorf, Germany

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2022年 / 33卷 / 11期

关键词：

FATTY LIVER-DISEASE; RECEPTOR-BETA AGONISTS; HORMONE RECEPTOR; NONALCOHOLIC STEATOHEPATITIS; SUBCLINICAL HYPOTHYROIDISM; INSULIN-RESISTANCE; GLOBAL EPIDEMIOLOGY; ENERGY-EXPENDITURE; HEPATIC STEATOSIS; GENE-EXPRESSION;

D O I：

10.1016/j.tem.2022.08.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nonalcoholic fatty liver disease (NAFLD) is a worldwide rising challenge because of hepatic, but also extrahepatic, complications. Thyroid hormones are master regulators of energy and lipid homeostasis, and the presence of abnormal thyroid function in NAFLD suggests pathogenic relationships. Specifically, persons with hypothyroidism feature dyslipidemia and lower hepatic beta-oxidation, which favors accumulation of triglycerides and lipotoxins, insulin resistance, and subsequently de novo lipogenesis. Recent studies indicate that liver-specific thyroid hormone receptor beta agonists are effective for the treatment of NAFLD, likely due to improved lipid homeostasis and mitochondrial respiration, which, in turn, may contribute to a reduced risk of NAFLD progression. Taken together, the possible coexistence of thyroid disease and NAFLD calls for increased awareness and optimized strategies for mutual screening and management.

引用

页码：755 / 768

页数：14

共 113 条

[1] Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline [J].

Aller, Rocio ;

Fernandez-Rodriguez, Conrado ;

lo Iacono, Oreste ;

Banares, Rafael ;

Abad, Javier ;

Antonio Carrion, Jose ;

Garcia-Monzon, Carmelo ;

Caballeria, Joan ;

Berenguer, Marina ;

Rodriguez-Peralvarez, Manuel ;

Lopez Miranda, Jose ;

Vilar-Gomez, Eduardo ;

Crespo, Javier ;

Garcia-Cortes, Miren ;

Reig, Maria ;

Maria Navarro, Jose ;

Gallego, Rocio ;

Genesca, Joan ;

Teresa Arias-Loste, Maria ;

Jesus Pareja, Maria ;

Albillos, Agustin ;

Muntane, Jordi ;

Jorquera, Francisco ;

Sola, Elsa ;

Hernandez-Guerra, Manuel ;

Angel Rojo, Miguel ;

Salmeron, Javier ;

Caballeria, Llorenc ;

Diago, Moises ;

Molina, Esther ;

Bataller, Ramon ;

Romero-Gomez, Manuel .

GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (05) :328-349

[2] The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials [J].

Angelidi, Angeliki M. ;

Papadaki, Angeliki ;

Nolen-Doerr, Eric ;

Boutari, Chrysoula ;

Mantzoros, Christos S. .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 129

[3] Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome [J].

Angelin, Bo ;

Kristensen, Jens D. ;

Eriksson, Mats ;

Carlsson, Bo ;

Klein, Irwin ;

Olsson, Anders G. ;

Ridgway, E. Chester ;

Ladenson, Paul W. .

JOURNAL OF INTERNAL MEDICINE, 2015, 277 (03) :331-342

[4] Lipid lowering with thyroid hormone and thyromimetics [J].

Angelin, Bo ;

Rudling, Mats .

CURRENT OPINION IN LIPIDOLOGY, 2010, 21 (06) :499-506

[5]

[Anonymous], 1972, JAMA, V220, P996

[6] Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis [J].

Apostolopoulou, Maria ;

Gordillo, Ruth ;

Koliaki, Chrysi ;

Gancheva, Sofia ;

Jelenik, Tomas ;

De Filippo, Elisabetta ;

Herder, Christian ;

Markgraf, Daniel ;

Jankowiak, Frank ;

Esposito, Irene ;

Schlensak, Matthias ;

Scherer, Philipp E. ;

Roden, Michael .

DIABETES CARE, 2018, 41 (06) :1235-1243

[7] Thyroid hormone receptor β mutants:: Dominant negative regulators of peroxisome proliferator-activated receptor γ action [J].

Araki, O ;

Ying, H ;

Furuya, F ;

Zhu, XG ;

Cheng, SY .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) :16251-16256

[8] Distinct Dysregulation of Lipid Metabolism by Unliganded Thyroid Hormone Receptor Isoforms [J].

Araki, O. ;

Ying, H. ;

Zhu, X. G. ;

Willingham, M. C. ;

Cheng, S. Y. .

MOLECULAR ENDOCRINOLOGY, 2009, 23 (03) :308-315

[9] Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Gossios, Thomas D. ;

Griva, Theodora ;

Anagnostis, Panagiotis ;

Kargiotis, Konstantinos ;

Pagourelias, Efstathios D. ;

Theocharidou, Eleni ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

LANCET, 2010, 376 (9756) :1916-1922

[10] Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study [J].

Bano, Arjola ;

Chaker, Layal ;

Plompen, Elisabeth P. C. ;

Hofman, Albert ;

Dehghan, Abbas ;

Franco, Oscar H. ;

Janssen, Harry L. A. ;

Murad, Sarwa Darwish ;

Peeters, Robin P. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (08) :3204-3211

← 1 2 3 4 5 6 7 8 9 10 →